Genetically haploidentical stem cell transplantation for acute leukemia

被引：19

作者：

Rowe, JM ^{[1
]}

Lazarus, HM

机构：

[1] Technion Israel Inst Technol, Dept Hematol & Bone Marrow Transplantat, Rambam Med Ctr, IL-31096 Haifa, Israel

[2] Univ Hosp Cleveland, Ireland Canc Ctr, Dept Med, Cleveland, OH 44106 USA

[3] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel

来源：

BONE MARROW TRANSPLANTATION | 2001年 / 27卷 / 07期

关键词：

haploidentical transplantation; acute leukemia;

D O I：

10.1038/sj.bmt.1702856

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Genetically haploidentical stem cell transplants have been performed for several decades, mostly for patients with advanced acute leukemia. Such transplants are an option for those patients who do not have a histocompatible sibling donor. The historical data have been disappointing due to graft-versus-host disease, engraftment failure and delayed immune reconstitution. Recent modifications and new technological developments have led to more encouraging clinical results, Haploidentical transplantation is immediately available to the majority of patients with acute leukemia and is an acceptable alternative to matched unrelated donor transplantation.

引用

页码：669 / 676

页数：8

共 74 条

[41]

LAZARUS HM, 2001, IN PRESS GRAFT

[42] Natural killer cells weakly resist engraftment of allogeneic, long-term, multilineage-repopulating hematopoietic stem cells [J].

Lee, LA ;

Sergio, JJ ;

Sykes, M .

TRANSPLANTATION, 1996, 61 (01) :125-132

[43] ADOPTIVE IMMUNOTHERAPY EVALUATING ESCALATING DOSES OF DONOR LEUKOCYTES FOR RELAPSE OF CHRONIC MYELOID-LEUKEMIA AFTER BONE-MARROW TRANSPLANTATION - SEPARATION OF GRAFT-VERSUS-LEUKEMIA RESPONSES FROM GRAFT-VERSUS-HOST DISEASE [J].

MACKINNON, S ;

PAPADOPOULOS, EB ;

CARABASI, MH ;

REICH, L ;

COLLINS, NH ;

BOULAD, F ;

CASTROMALASPINA, H ;

CHILDS, BH ;

GILLIO, AP ;

KERNAN, NA ;

SMALL, TN ;

YOUNG, JW ;

OREILLY, RJ .

BLOOD, 1995, 86 (04) :1261-1268

[44]

MALILAY GP, 1989, BONE MARROW TRANSPL, V4, P107

[45] Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program [J].

McGlave, PB ;

Shu, XO ;

Wen, WQ ;

Anasetti, C ;

Nadermanee, A ;

Champlin, R ;

Antin, JH ;

Kernan, NA ;

King, R ;

Weisdorf, DJ .

BLOOD, 2000, 95 (07) :2219-2225

[46] LATE INFECTIONS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION - COMPARISON OF INCIDENCE IN RELATED AND UNRELATED DONOR TRANSPLANT RECIPIENTS [J].

OCHS, L ;

SHU, XO ;

MILLER, J ;

ENRIGHT, H ;

WAGNER, J ;

FILIPOVICH, A ;

MILLER, W ;

WEISDORF, D .

BLOOD, 1995, 86 (10) :3979-3986

[47]

OREILLY RJ, 1985, TRANSPLANT P, V17, P455

[48] Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplants [J].

Passweg, JR ;

Kühne, T ;

Gregor, M ;

Favre, G ;

Avoledo, P ;

Tichelli, A ;

Gratwohl, A .

BONE MARROW TRANSPLANTATION, 2000, 26 (10) :1033-1036

[49]

Perruccio K, 2000, BLOOD, V96, p555A

[50] Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient [J].

Petersdorf, EW ;

Gooley, TA ;

Anasetti, C ;

Martin, PJ ;

Smith, AG ;

Mickelson, EM ;

Woolfrey, AE ;

Hansen, JA .

BLOOD, 1998, 92 (10) :3515-3520

← 1 2 3 4 5 6 7 8 →